BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Late nights and skipping breakfast linked to increased heart disease risk, especially in men October 30, 2023 Nanomedicine using gas bubbles offers hope for lung cancer treatment November 22, 2024 Pandemic impact: Significant rise in sleep disturbances among children and adolescents worldwide January 10, 2024
Late nights and skipping breakfast linked to increased heart disease risk, especially in men October 30, 2023
Pandemic impact: Significant rise in sleep disturbances among children and adolescents worldwide January 10, 2024